Cance

C2i Genomics, a cancer intelligence company, has launched its C2inform minimal residual disease (MRD) test across Europe after obtaining CE-IVD marking in the EU, UK and Switzerland.   The company also announced the completion of several clinical trials across the globe, including cancer centers in Europe, US and Singapore.   The new clinical data will be presented […]